Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® ...
Morningstar

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the ...
Nasdaq

Jazz Pharma Reports Positive Phase 3 HERIZON-GEA-01 Results

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without ...

Revolution Medicines (RVMD) Reports Positive Zoldonrasib Trial Data Ahead Of Phase 3

Revolution Medicines (NasdaqGS:RVMD) reported positive Phase 1/2 data for zoldonrasib-based combination regimens in RAS G12D metastatic pancreatic cancer. The new results show compelling antitumor ...
Seeking Alpha

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...